Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways

BACKGROUND: The most common clinical outcome observed after treatment with immune checkpoint inhibitor antibodies is disease stabilization. Using vaccines to generate high levels of tumor antigen-specific T-helper 1 (Th1), we show that tumors not eradicated by vaccination demonstrate prolonged disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Cecil, Denise, Park, Kyong Hwa, Curtis, Benjamin, Corulli, Lauren, Disis, Mary (Nora)
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993179/
https://www.ncbi.nlm.nih.gov/pubmed/33762321
http://dx.doi.org/10.1136/jitc-2021-002355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993179/
https://www.ncbi.nlm.nih.gov/pubmed/33762321
http://dx.doi.org/10.1136/jitc-2021-002355

Ejemplares similares